Covidien PLC (COV): Today's Featured Health Services Winner
(
) pushed the Health Services industry higher today making it today's featured health services winner. The industry as a whole closed the day up 0.8%. By the end of trading, Covidien rose $1.30 (2.2%) to $59.35 on light volume. Throughout the day, 1,561,798 shares of Covidien exchanged hands as compared to its average daily volume of 3,371,700 shares. The stock ranged in a price between $58.71-$59.38 after having opened the day at $58.80 as compared to the previous trading day's close of $58.05. Other companies within the Health Services industry that increased today were:
(
), up 15.7%,
(
), up 10.5%,
(
), up 9.6% and
Arrhythmia Research Technology
(
), up 9.2%.
Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $27.3 billion and is part of the health care sector. Shares are up 0.5% year to date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.
TheStreet Ratings rates
Covidien
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Covidien Ratings Report.
On the negative front,
(
), down 69.2%,
(
), down 7.4%,
(
), down 6.8% and
(
), down 5.9%.
- Use our health services section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health services industry could consider
Health Care Select Sector SPDR
(
) while those bearish on the health services industry could consider
ProShares Ultra Short Health Care
(
).
- Find other investment ideas from our top rated ETFs lists.
null